Impact of sleep status on lung adenocarcinoma risk: a prospective cohort study

OBJECTIVE

The association between sleep status and lung adenocarcinoma risk was analyzed using long-term follow-up data from 60,443 patients over the period 2016-2022 to provide a reference for exploring the association between sleep status and lung adenocarcinoma development.

PATIENTS AND METHODS

Based on long-term follow-up data, a total of 60,443 people were included. Sleep data collected for the study included insomnia symptoms, lunch break habits, and sleep duration. A sleep score (0-3) was constructed based on difficulty falling asleep, premature awakening and sleep duration. Proportional risk regression models were used to analyze the association between each sleep factor, sleep score and lung cancer risk.

RESULTS

The study population was followed up for 9.9 ± 4.8 years and a total of 307 cases of lung adenocarcinoma were first recorded during the follow-up period. After controlling for potential confounders, the risk ratios (HR) for lung adenocarcinoma in those with difficulties going asleep or waking up too early were 1.12 (95% CI: 1.02-1.14) and 1.07 (95% CI: 1.01-1.11), respectively, compared to those without symptoms of insomnia. The HR for lung adenocarcinoma in those with less than 7 h of sleep [HR = 1.17 (95% CI: 1.05-1.21)] was compared to those with ≥ 7 h of sleep per day. Compared to those with a sleep score of 3 (highest quality sleep), those with a sleep score of 2, 1 and 0 corresponded to HR of 1.06 (95% CI: 1.01-1.12), 1.11 (95% CI: 1.09-1.18) and 1.15 (95% CI: 1.01-1.32) respectively.

CONCLUSIONS

Patients who suffer from insomnia or have a short sleep schedule are at increased risk of developing lung cell cancer. Sleep has an important impact on health and improving sleep conditions can reduce the incidence of lung cancer.

[Effect of vitamin C (V.C) on thermal sensitivity of Lewis tumor]

In this paper, the effect of V.C on thermal sensitivity of the tumor and normal tissues was studied. Average peak reaction and RD50 (50% reaction dosage) were used to evaluate the effect of V.C on thermal sensitivity of the normal tissue. Tumor cure rate and TCD50 (50% tumor cure dosage) were used to evaluate the effect of V.C on that of the tumor tissue. In all mice injected by V.C locally, the average peak reaction markedly increased, RD50 decreased by 1-2 fold; the tumor cure rate was obviously elevated, TCD50 was significantly reduced except those treated by 20' hyperthermia. TGF (therapeutic gain factor) was 1.76. These results indicate that V.C can increase the thermal sensitivity of tumor and normal tissues but the effect on tumor tissue is selective.

[Radiotherapy of chordoma--a report of 10 patients]

A consecutive series of 10 patients with chordoma was treated in our hospital from 1956 to 1982. Six were male and four were female. The age ranged 19 approximately 52 years. Eight lesions occurred in the base of sphenoid and two in the sacrum. All were treated by postoperative radiotherapy with a medium dose of 4,500 approximately 6,000 rad. Recurrent patients were given a hyperfractionated radiotherapy (100 rad, 4/D, at intervals of 3 hours, total dose 2000 rad). The 5 and 10 year survival rates were 75% and 50%. No complications were found after radiation. In this paper, literature on chordoma and radiotherapy for chordoma are reviewed. An optimal schedule is proposed: operation be the choice of treatment, which be as thorough as possible; two months after the operation, radiotherapy be given at a suitable dose of 5000 approximately 6000 rad; the recurrent lesions be treated by hyperfractionated radiotherapy.